Modality
ERT
MOA
PD-L1i
Target
MALT1
Pathway
Proteasome
Pancreatic Ca
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
Oct 2022
→ Feb 2025
Phase 1Current
NCT03006752
2,063 pts·Pancreatic Ca
2022-10→2025-02·Completed
2,063 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-281.1y agoPh2 Data· Pancreatic Ca
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025
P1/2
Complet…
Catalysts
Ph2 Data
2025-02-28 · 1.1y ago
Pancreatic Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03006752 | Phase 1/2 | Pancreatic Ca | Completed | 2063 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 |